Using HTA methods and early value assessment to optimize evidence generation plans
February 14th, 2024 – 9am-10am ET / 2:00-3:00pm GMT
moderated by Noemi Muszbek
HE Director, Partner, Visible Analytics
Ascenian and Visible Analytics are co-hosting a live webinar this February.
Join our experts as they answer your questions and explore how early HTA activities and early value assessment can inform asset valuation, investment decisions, study design and market access strategy.
Prof. Neil Hawkins
HTA Director, Partner, Visible Analytics, UK
Sr. Director, Pricing, Reimbursement, & Market Access, Regenxbio, USA
Prof. Dr. Marc Bardou
Economic and Public Health Committee, HAS, France
Dr. Susanne Michel
former Department of Health in Berlin, Ascenian, Germany